Join our daily newsletter At The Bell to receive exclusive market insights
- Archer Materials (AXE) has demonstrated it can fabricate nano-size biosensor components on silicon wafers to successfully develop its biochip
- The biochip is being developed to aid the detection of diseases that can affect the respiratory system
- The company has now miniaturised key biosensor components to chip-formats on silicon by nano-fabrication, translating to approximately one million components with a one-centimetre-squared area
- Following the success, Archer has brought on more permanent staff to pursue areas of highest value-added activities in its biochip development
- Company shares are trading flat at 98.5 cents
Archer Materials (AXE) has demonstrated it can fabricate nano-size biosensor components on silicon wafers to successfully develop its biochip.
Archer’s biochip uses graphene-based materials as integrated circuits to form the key sensing elements in its lab-on-a-chip technology. The biochip is aimed at addressing the complex detection of diseases affecting the respiratory system, as they remain the world’s most deadly communicable diseases.
The company announced in November it was aiming to miniaturise key biosensor components of its biochip technology onto silicon wafers.
This development milestone is required before the company can validate commercial advantages of ultra-sensitivity and device integration. This will also enable high-volume chip production required for any future retail applications of the biochip.
Prior to the company using local semiconductor foundry fabrication techniques, it was limited to roughly one sensor per one centimetres squared.
The company has now miniaturised key biosensor components to chip-formats on silicon by nano-fabrication, translating to approximately one million components with a one-centimetre-squared area.
“Archer has attracted talented technologists to work on a promising, potential solution to a global challenge that has significant socio-economic implications. As we ramp up our biochip development, we will strategically bridge industry capability gaps, and where possible, locally,” said Archer CEO Dr Mohammad Choucair.
Following the success, the company has recently brought on permanent staff to pursue areas of highest value-added activities in its biochip development.
Archer shares are trading flat at 98.5 cents at 11:50 am AEDT.
